StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study
Status:
Active, not recruiting
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The SAVER pilot is a randomized, open-label pilot study to determine the feasibility of
recruitment. In addition to feasibility data, the investigators will carefully collect
clinical data to determine if rosuvastatin can reduce post-thrombotic syndrome (PTS) in
venous thromboembolism (VTE) patients.
Eligible consenting patients who developed acute, symptomatic, and objectively confirmed
proximal leg deep vein thrombosis (DVT) and/or PE will be randomized and equally allocated to
2 trial arms, either the treatment group (rosuvastatin tablet (20 mg/day) or the control
group (usual care). The pilot trial consists of up to 4 study contacts over 6 months:
screening, randomization, telephone follow-up (90 days), and final study visit (180 days).